AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Compliance
Description: Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Compliance
Description: Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
Study NCT03423238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calorie-Restricted Diet
Description: Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
Study NCT03423238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Modification
Description: During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-Loss Compliance
Description: Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
Study NCT03423238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Participants have one meeting with the Rehab dietitian upon starting.
Study NCT03330678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Description: Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
Study NCT03030352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How-to Parenting Program
Description: The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
Study NCT04372550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and aerobic exercise in addition to standard of care rehabilitation
Study NCT04372550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study NCT04372550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study NCT01769664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
Description: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Study NCT01769664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac® Topical Gel
Description: Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
Study NCT01769664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
Study NCT04351607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oleovital® Eisen Forte
Description: 60 mg daily oral Supplementation for 3 to 6 weeks
Study NCT04351607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleovital® Eisen Forte
Description: 60 mg daily oral Supplementation for 3 to 6 weeks
Study NCT02758600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise rehabilitation protocol
Description: Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
Study NCT02388464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (low dose) administered as single intravenous infusion over 4 hours
Study NCT02388464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
Study NCT02388464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Description: MTP-131 (high dose) administered as single intravenous infusion over 4 hours
Study NCT02388464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
Study NCT03496064 — intervention group
Intervention type: OTHER
Intervention: Successful reperfusion
Description: Defined as modified Thrombolysis in Cerebral Infarction 2b/3
Study NCT02882438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infected group
Description: Ginkgo Biloba in different dosage forms
Study NCT02882438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: placebo without Ginkgo Biloba
Study NCT02526953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
Study NCT02526953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study NCT02526953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study NCT02526953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycins
Description: 10 mg/m2, IV, on day 1. Number of infusions: 1.
Study NCT02526953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycins
Description: 12 mg/m2, IV, on day 1. Number of infusions: 1.
Study NCT02526953 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
Study NCT02526953 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
Study NCT01294137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilatory polygraphy
Study NCT01074476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: 750mg glucosamine sulphate (oral tablets), twice per day for 3 months
Study NCT01074476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, twice per day for 3 months
Study NCT01872585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization based therapy
Description: 12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
Study NCT02279368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Counselling and safeguarding
Study NCT03964168 — intervention group
Intervention type: DRUG
Intervention: Biologic Agent
Description: Patients who discontinued a bioloic agent
Study NCT02972346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
Study NCT01564212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard airflow with forced air warming.
Description: Subjects will lie on operating room bed with standard airflow and forced air warming.
Study NCT01564212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laminar airflow with surgical drapes
Study NCT01564212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laminar airflow with forced air warming
Description: Subjects will lie on operating room bed with laminar airflow and forced air warming.
Study NCT01564212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard airflow with surgical drapes
Description: Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
Study NCT02777359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the transcatheter closure of PFO
Description: the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
Study NCT02041390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
Study NCT02041390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reminder
Description: After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
Study NCT02041390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional reminder
Description: After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
Study NCT02515968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
Study NCT02515968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT01491061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, 1,000 mg twice 12 hours apart prior to PCI
Study NCT01491061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: os, two doses 12 hours apart prior to PCI
Study NCT03617601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MET
Description: Testing of the metabolic equivalent of task before aortic procedure
Study NCT03097523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Thigh Cuff
Description: The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
Study NCT00162214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib + Ketoconazole
Description: Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
Study NCT03107858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Study NCT03107858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Study NCT03582046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Perfusion Pressure (APP)
Description: Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
Study NCT03582046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mean Arterial Pressure (MAP)
Description: Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
Study NCT02445105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Autism Navigator Enhanced Practice
Description: Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
Study NCT02445105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Engagement plus Autism Navigator
Description: Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
Study NCT04628702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tablet training
Description: 1.5 year training period
Study NCT02880228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02880228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02880228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02880228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03162796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
Study NCT00303784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: 3.6mg implant, in pre-filled syringe
Study NCT03162796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as SC injection.
Study NCT00303784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Study NCT02376231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for EOC with trial (PJ) device (PlasmaJet)
Description: Debulking surgery for EOC using PJ device
Study NCT03196102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTI
Description: Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
Study NCT03196102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cigarette smoking military tailored pamphlet
Description: The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
Study NCT03196102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette smoking military tailored pamphlet
Description: The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
Study NCT03196102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation intervention
Description: This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
Study NCT04380116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soberlink
Description: Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
Study NCT03722966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.